Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis CEO Elected to Board of Affitech A/S

Jul 13, 2011 1:45:12 PM

Geneva, Switzerland (PRWEB) July 13, 2011 – Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today the Company’s CEO, Dr. Igor Fisch, has been elected to Affitech’s (NASDAQ OMX Copenhagen) board of directors effective April 28, 2011. Denmark-based Affitech is a biotechnology company dedicated to the discovery and development of human antibody-based therapeutics in cancer and other diseases with unmet medical needs.

“I am excited to be joining Affitech at this stage when it is transitioning into a more development-focused company,” said Igor Fisch, PhD, CEO of Selexis. “I look forward to providing leadership at the Board level particularly in manufacturing and commercial activities.”

About Affitech
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation, and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules. Affitech co-develops its two lead antibody drug candidates AT001/r84 and AT008/CCR4 with Russian partner IBC Generium. Further information is available at

Topics: 2011